Tvardi receives FDA pre-IND feedback for TTI-109 in inflammatory bowel disease
Tvardi Therapeutics announced receipt of FDA written responses to its pre-IND meeting request for TTI-109, the company's next-generation oral STAT3 inhibitor for inflammatory bowel disease. The FDA agreed that the proposed nonclinical studies are appropriate to support a Phase 2 trial and provided guidance on dosing, study design, and patient selection. The company plans to submit an IND in 2027, with Phase 2 initiation subject to FDA clearance and additional funding availability. New analysis of Phase 1 exposur...
Key takeaways
FDA pre-IND feedback supports TTI-109 development approach for ulcerative colitis, with flexibility to pursue Crohn's disease either in parallel or sequentially.
Phase 2 trial nonclinical study plan deemed appropriate by FDA; guidance provided on dosing, study design, and patient selection.
IND submission targeted for 2027, with Phase 2 initiation contingent on FDA IND clearance and additional funding.
Phase 1 exposure analysis supports preferential STAT3 inhibition with minimal predicted STAT1 and STAT5 inhibition at proposed clinical doses.
Company believes selectivity profile may differentiate TTI-109 from JAK inhibitors, which carry boxed warnings for serious infections, malignancy, and cardiovascular events.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow TVRD in real time
Get material earnings, filing, IR, and earnings-call alerts by email.